Viyash Scientific Ltd (VIYASH) — shareholding pattern, promoter holding, financials and share price
About Viyash Scientific Ltd (VIYASH)
Viyash Scientific Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as VIYASH and on the BSE under scrip code 512529. Its ISIN is INE807F01027.
Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries.
Viyash Scientific Limited, formerly Sequent Scientific Limited, is engaged in the pharmaceutical business with a focus on animal health, formulations, and API. The company has shown solid financial performance in Q3 FY26, with revenues of ₹8,584 million and EBITDA growing by 64% YoY. It has achieved significant margin expansion, reflecting strong operational efficiencies and strategic cost optimization.
The merger with Sequent Scientific Limited has enabled Viyash to unlock synergies across various business units, enhancing R&D, manufacturing capabilities, and market reach. This transformative merger has laid a strong foundation for sustained profitability and business growth.
Listed peers in Pharmaceuticals: Corona Remedies Ltd, Marksans Pharma Ltd, Shilpa Medicare Ltd, Procter & Gamble Health Ltd, Akums Drugs & Pharmaceuticals Ltd, Blue Jet Healthcare Ltd.
Valuation & Returns
10 Jul 2026At ₹278.35 a share on 10 Jul 2026, Viyash Scientific Ltd (VIYASH) was valued at a price-to-earnings ratio of 79.97x against an industry P/E of 36.41x and a price-to-book of 17.26x on a book value of ₹16.13 per share as of Mar 2025. Solomo computes return on equity of 21.59% and return on capital employed of 26.14% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 79.97x
- Industry P/E
- 36.41x
- P/B
- 17.26x
- EPS (TTM)
- ₹3.48
- Book value / share
- ₹16.13
- ROE
- 21.59%
- ROCE
- 26.14%
- ROA
- 9.49%
- Debt / equity
- 0.68x
- Dividend yield
- 0%
- EBITDA margin
- 18.97%
- 52-week range
- ₹166.2 – ₹297.9
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Viyash Scientific Ltd (VIYASH) reported revenue of ₹3,420 crore, net profit of ₹225 crore and earnings per share of ₹4.06. That compares with revenue of ₹1,551 crore and net profit of ₹32 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹920 crore and net profit ₹66 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 1,413 | 1,421 | 1,370 | 1,551 | 3,420 |
| Net profit (₹ cr) | 45 | -122 | -30 | 32 | 225 |
| EPS (₹) | 1.65 | -4.86 | -1.44 | 0.87 | 4.06 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -8.81% | -4.75% | -6.72% | 13.26% |
| Profit growth | 4.77% | -5.84% | 2.19% | 208.95% |
| Stock price CAGR | 8% | -2% | 46% | 48% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 61.31% of Viyash Scientific Ltd (VIYASH) (unchanged from the previous quarter), foreign institutional investors (FII) hold 4.5% and domestic institutional investors (DII) hold 3.75%. Market capitalisation was ₹12,160 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: HARIBABU BODEPUDI 2.77%, QUANT MUTUAL FUND - QUANT SMALL CAP FUND 2.58%, KALIDINDI SRIHARI RAJU 2.35%, NARASIMHA REDDY DUTHALA 1.27%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 61.31% | - | 4.5% | 3.75% | 38.6% |
| Mar 2026 | 61.31% | - | 2.94% | 7.99% | 38.59% |
| Dec 2025 | 61.41% | - | 3.16% | 7.36% | 38.49% |
| Sep 2025 | 52.33% | - | 5.91% | 12.91% | 47.51% |
| Jun 2025 | 52.61% | - | 6.15% | 12.99% | 47.23% |
| Mar 2025 | 52.61% | - | 6.05% | 12.82% | 47.23% |
| Dec 2024 | 52.61% | - | 6.1% | 12.02% | 47.23% |
| Sep 2024 | 52.76% | - | 6.45% | 9.99% | 47.07% |